{"prompt": "['4.2.3', 'Modalities for recruitment, inclusion and follow-up', 'Recruiting and informing the patients of the study in progress will take place during a', 'standard ENT consultation or in the Reference Center or Skill Center for HHT.', 'Patients will be included on the day the treatment is prescribed.', 'The treatment is self-administered by patients, twice daily, for 6 weeks.', 'The follow-up period will be scheduled as follows:', '-', 'at each consultation, an ENT examination and a clinical examination including', 'measurement of heart rate and blood pressure will be performed', 'Completion of epistaxis grids', 'Inclusion', '+ drug prescription', 'Treatment 6 weeks', 'D1 to D42', '-6 weeks', 'V1', 'D8', 'D15', 'D22', 'D31', 'V2', 'V3', '-42 days', 'Day 0', 'Day 43', 'Day 85', 'Consultations', 'Consultations', 'Consultations', '= blood sample', 'Figure 7: Diagram of the running of the study', '4.2.4', 'Inclusion criteria', '- Age 18 years.', '- Patients who have given their free, informed and signed consent.', '- Patients affiliated to a social security scheme or similar.', '- Patients monitored for clinically confirmed HHT (presence of at least 3 Cura\u00e7ao', 'criteria) and/or confirmed by molecular biology.', '-', 'Patient presenting nosebleeds with total duration > 30 minutes for 6 weeks prior to', 'the time of inclusion justified by completed follow-up grids.', '4.2.5', 'Exclusion criteria', '-', 'Women who are pregnant or nursing (lactating), women of child-bearing potential', 'without reliable contraception.', '- Patients not affiliated to a social security scheme.', '-', 'Patients who are protected adults under the terms of the law (French Public Health', 'Code).', '- Refusal to consent.', '- Patients for whom the diagnosis of HHT has not been confirmed clinically and/or by', 'molecular biology.', '-', 'Participation in another clinical trial wich may interfere with the proposed trial', '(judgment of the investigator).', 'Page 30 of 64']['- Patients who have undergone nasal surgery in the 6 weeks prior to inclusion.', '- Known hypersensitivity to macrolides in general, to tacrolimus or to any of the', 'excipients.', '-', \"Patient with an inherited skin barrier disease such as Netherton's syndrome, lamellar\", 'ichtyosis, generalized erythroderma, graft-versus-host skin disease, or suffering from', 'generalized erythroderma.', '- Patient with CYP3A4 inhibotors treatment, e.g. erythromycin, itraconazole,', 'ketoconazole and diltiazem.', '- Patients who have incompletely filled in the nosebleed grids in the 6 weeks preceding', 'the treatment. If there is missing data for more than 7 days (10%), the patient cannot', 'be included.', '- Patients who do not present nosebleeds with a total duration of > 30 minutes for 6', 'weeks prior to the time of inclusion.', '- Patients with ongoing immunosuppressive treatment', '- Patients with known and symptomatic immune deficiency.', '4.3 Assessment criteria for the study product', '4.3.1', 'Main judgement criterion', 'The main judgement criterion is the percentage of patients experiencing an', 'improvement in their nosebleeds. An improvement is defined as a 30% reduction in', 'the total duration of nosebleeds over 6 weeks after treatment, compared with the', 'duration of the nosebleeds in the 6 weeks before the treatment.', '4.3.2 Secondary judgement criteria', '1. Adverse Events (AE) and Severe Adverse Events (SAE) observed throughout the', 'study (clinical examination, epistaxis grids, ENT examination at each visit before', 'and after the treatment). Additionally, all patients are contacted by phone after 15', 'and 30 days of treatment in order to collect data on tolerance and observance of', 'the treatment.', '2. Clinical efficacy criteria:', '-', 'Nosebleed duration will be evaluated by the nosebleed monitoring grids', 'completed by the patient (Appendix 1), collected at inclusion (V1): observation', 'of the nosebleeds in the 6 weeks prior to inclusion, at the end of the treatment', '(V2): observation of the nosebleeds in the 6 weeks during treatment, and at the', 'end of the study (V3): observation of the nosebleeds in the 6 weeks after the', 'end of the treatment.', '-', 'Progress in the number of nosebleeds. This criterion will be evaluated by the', 'nosebleed monitoring grids completed by the patient (Appendix 1) collected at', 'inclusion (V1): observation of the nosebleeds in the 6 weeks prior to inclusion,', 'at the end of the treatment (V2): observation of the nosebleeds in the 6 weeks', 'during treatment, and at the end of the study (V3): observation of the', 'nosebleeds in the 6 weeks after the end of the treatment.', '-', 'Comparison of the number of red blood cell transfusions between inclusion (V1)', '(collected over 6 weeks before treatment), the end of the treatment (V2)', '(collected over 6 weeks of treatment) and at the end of the study (V3) (collected', 'over 6 weeks after the end of the treatment).', '-', 'Progress in the scores obtained in the SF36 quality of life questionnaire', 'Page 31 of 64']\n\n###\n\n", "completion": "END"}